ARVINAS, INC. (ARVN) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-01

Key Insights

FDA approval of VEPPANU (vepdegestrant) granted ahead of the June 5, 2026 PDUFA date, marking the first-and-only FDA-approved PROTAC protein degrader for ER+/HER2-/ESR1-mutated advanced or metastatic breast cancer, representing a significant clinical validation of Arvinas' platform technology.
Company will receive a $50 million FDA approval milestone payment from Pfizer under their July 2021 collaboration agreement, though this will be partially offset by payments owed to Yale University under their June 2024 amended license agreement.
Commercialization pathway remains on track with Arvinas and Pfizer expected to announce selection of a third-party commercialization partner, indicating active progress toward market launch and revenue generation.

Want the newest filings?

This analysis covers the filing from 2026-05-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-18

Arvinas announced positive Phase 1 data for its investigational PROTAC drug ARV-102, showing greater than 50% degradation of the LRRK2 protein in the cerebrospinal fluid of Parkinson's disease patients after 28 days of treatment.
The drug was well-tolerated, with no serious adverse events reported, and demonstrated dose-dependent brain penetration and pharmacodynamic effects.
Based on these results, Arvinas plans to continue developing ARV-102 for neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction, including initiating a Phase 1b trial in progressive supranuclear palsy in Q2 2026.

Filed: 2026-02-24

Arvinas, Inc. announced its financial results for the fourth quarter and full year 2025, indicating the company's financial performance during this period.
The company provided a corporate update, which may include information about its business operations, product development, or other strategic initiatives.
As the filing is an 8-K, it suggests the company is reporting a material event or change in its business, which could be of interest to investors.

Filed: 2026-02-12

Arvinas has appointed a new President, CEO and Board Chair, indicating a change in leadership and potential strategic shift for the company.
The incoming CEO, Randy Teel, has 20 years of biopharmaceutical industry experience and has held various roles at Arvinas since 2018, providing continuity in the company's operations.
The new employment agreement for the CEO includes a base salary, performance-based bonus, and equity grants, aligning his compensation with shareholder interests.

Other reports for ARVINAS, INC.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.